SUPN241220P42000
- 0.00
- 0.000.00%
Supernus Pharmaceuticals Newsroom
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Supernus Pharmaceuticals (SUPN) and Skye Bioscience (SKYE)
Piper Sandler Sticks to Their Hold Rating for Supernus Pharmaceuticals (SUPN)
Screening For Black Friday Bargains In The Stock Market
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
Numerous Supernus Pharmaceuticals Insiders Sold Stock: Not A Positive Omen
US Manufacturing Index Rises To 43, Highest Since 2020
Supernus Pharmaceuticals(SUPN.US) Officer Sells US$4.54 Million in Common Stock
Form 144 | Supernus Pharmaceuticals(SUPN.US) Officer Proposes to Sell 4.54 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 8, $Supernus Pharmaceuticals(SUPN.US)$ Officer JACK A KHATTAR intends to sell 125K shares of its common stock on Nov 8, with a total market value of approximately $4.54
Supernus Pharmaceuticals Insider Sold Shares Worth $520,480, According to a Recent SEC Filing
Supernus Pharmaceuticals(SUPN.US) Officer Sells US$4.59 Million in Common Stock
Form 144 | Supernus Pharmaceuticals(SUPN.US) Officer Proposes to Sell 4.58 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 7, $Supernus Pharmaceuticals(SUPN.US)$ Officer JACK A KHATTAR intends to sell 125K shares of its common stock on Nov 7, with a total market value of approximately $4.58
Earnings Call: Supernus Pharmaceuticals Reported a Significant Increase in Total Revenue
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $36
Piper Sandler Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript Summary
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
Strong Q3 Performance and Promising Future for Supernus Pharmaceuticals Backed by Qelbree's Success